
Agile Therapeutics AGRX
Quarterly report 2024-Q2
added 08-12-2024
Agile Therapeutics Long Term Debt Current 2011-2026 | AGRX
Annual Long Term Debt Current Agile Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 366 K | 319 K | 175 K | 138 K | 172 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 366 K | 138 K | 234 K |
Long Term Debt Current of other stocks in the Drug manufacturers industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Evoke Pharma
EVOK
|
59.5 K | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
12.5 M | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
100 K | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
1.08 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
4.36 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
634 K | - | - | $ 142 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
468 K | $ 5.53 | 2.22 % | $ 82.1 M | ||
|
Cronos Group
CRON
|
337 K | $ 2.67 | 2.3 % | $ 1.02 B | ||
|
Harrow Health
HROW
|
887 K | $ 30.86 | 0.59 % | $ 1.13 B | ||
|
Athenex
ATNX
|
2.09 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
582 K | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
13 M | - | - | $ 11.5 B | ||
|
HEXO Corp.
HEXO
|
914 K | - | 2.45 % | $ 38.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
1.53 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
956 K | - | - | $ 28.9 M | ||
|
Bausch Health Companies
BHC
|
61 M | $ 5.5 | 3.29 % | $ 2.01 B | ||
|
Organogenesis Holdings
ORGO
|
4.95 M | $ 2.55 | 4.94 % | $ 323 M | ||
|
Pacira BioSciences
PCRX
|
8.89 M | $ 23.0 | 3.09 % | $ 1.06 B | ||
|
Canopy Growth Corporation
CGC
|
7.46 M | $ 1.03 | 4.06 % | $ 111 M | ||
|
Solid Biosciences
SLDB
|
2.1 M | $ 6.47 | 6.41 % | $ 566 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
58 K | $ 1.07 | 5.94 % | $ 1.33 M | ||
|
Aurora Cannabis
ACB
|
5.38 M | $ 3.47 | 5.15 % | $ 190 M | ||
|
Jupiter Wellness
JUPW
|
23.5 K | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
2.06 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
1.03 M | $ 1.07 | 2.88 % | $ 102 M | ||
|
Tilray
TLRY
|
2.47 M | $ 5.41 | 3.84 % | $ 3.34 B | ||
|
Evolus
EOLS
|
2.53 M | $ 6.59 | 2.49 % | $ 425 M | ||
|
Sundial Growers
SNDL
|
35.5 M | $ 1.44 | 4.35 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
3.5 M | $ 8.15 | 0.93 % | $ 417 M | ||
|
Veru
VERU
|
759 K | $ 2.17 | 2.84 % | $ 31.8 M | ||
|
Neoleukin Therapeutics
NLTX
|
3.05 M | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
778 K | $ 0.75 | -0.27 % | $ 3.02 M | ||
|
Assertio Holdings
ASRT
|
240 K | $ 23.44 | 0.13 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
301 K | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
613 K | - | - | $ 1.42 B | ||
|
PetIQ
PETQ
|
7.61 M | - | 1.64 % | $ 400 M | ||
|
Recro Pharma
REPH
|
1.1 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
911 K | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
483 K | $ 0.67 | 1.67 % | $ 33.5 M | ||
|
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
109 M | $ 16.59 | 2.6 % | $ 19.3 B | ||
|
Zomedica Corp.
ZOM
|
717 K | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
215 K | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
1.16 M | $ 0.82 | 2.71 % | $ 29.5 M | ||
|
Tricida
TCDA
|
2.74 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
71.6 K | $ 0.71 | -0.99 % | $ 3.05 M | ||
|
TherapeuticsMD
TXMD
|
975 K | $ 2.08 | 1.96 % | $ 24.1 M |